Desensitization: Achieving immune detente

Tissue Antigens

Volumn 77, Issue 1, 2011, Pages 3-8

  Zachary, A A ^a   Eng, H S ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Desensitization; Human leukocyte antigen antibodies; Incompatible transplantation; Positive crossmatch

Indexed keywords

ALEMTUZUMAB; BASILIXIMAB; BORTEZOMIB; CALCINEURIN INHIBITOR; CD20 ANTIBODY; CORTICOSTEROID; CYCLOSPORIN; CYTOMEGALOVIRUS ANTIBODY; DACLIZUMAB; DEOXYSPURGUALIN; ECULIZUMAB; HLA ANTIGEN; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; RAPAMYCIN; RITUXIMAB; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ANTIBODY RESPONSE; ANTIBODY TITER; B LYMPHOCYTE; BLOOD GROUP ABO INCOMPATIBILITY; CLINICAL PROTOCOL; CLINICAL TRIAL; DESENSITIZATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG SUBSTITUTION; GRAFT REJECTION; GRAFT SURVIVAL; HISTOINCOMPATIBILITY; HUMAN; IMMUNOMODULATION; IMMUNOREGULATION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIVER GRAFT REJECTION; LOW DRUG DOSE; PATIENT MONITORING; PLASMAPHERESIS; PRIORITY JOURNAL; REVIEW; SURVIVAL RATE; TRANSPLANTATION TOLERANCE;

DESENSITIZATION, IMMUNOLOGIC; GRAFT REJECTION; HLA ANTIGENS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS;

EID: 78650032792     PISSN: 00012815     EISSN: 13990039     Source Type: Journal    
DOI: 10.1111/j.1399-0039.2010.01596.x     Document Type: Review

References (56)

1. Jackson AM, Zachary AA. The problem of transplanting the sensitized patient whose problem is it? Front Biosci 2008: 13: 1396-412.
2. Rodey GE, Fuller TC. Public epitopes and the antigenic structure of the HLA molecules. Crit Rev Immunol 1987: 7: 229-67.
3. Larché M. Immunoregulation by targeting T cells in the treatment of allergy and asthma. Curr Opin Immunol 2006: 18: 745-50.
4. Ozdemir C. An immunological overview of allergen specific immunotherapy - subcutaneous and sublingual routes. Ther Adv Respir Dis 2009: 3: 253-63.
5. Knezevic-Maramic I, Kruskall MS. Intravenous immune globulins: an update for clinicians. Transfusion 2003: 43: 1460-80.
6. Sullivan KM, Kopecky KJ, Jocom J et al. Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation. N Engl J Med 1990: 323: 705-12.
7. Glotz D, Haymann J-P, Sansonetti N et al. Suppression of HLA-specific alloantibodies by high-dose intravenous immunoglobulins (IVIg). Transplantation 1993: 56: 335-7.
8. Jordan SC, Vo A, Bunnapradist S et al. Intravenous immune globulin treatment inhibits crossmatch positivity and allows for successful transplantation of incompatible organs in living-donor and cadaver recipients. Transplantation 2003: 76: 631-6.
9. Jordan SC, Tyan D, Stablein D et al. Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial. J Am Soc Nephrol 2004: 15: 3256-62.
10. Vo AA, Peng A, Toyoda M et al. Use of intravenous immune globulin and Rituximab for desensitization of highly HLA-Sensitized patients awaiting kidney transplantation. Transplantation 2010: 89: 1095-102.
11. Jordan SC, Toyoda M, Vo AA. Intravenous immunoglobulin a natural regulator of immunity and inflammation. Transplantation 2009: 88: 1-6.
12. John R, Lietz K, Burke E et al. Intravenous immunoglobulin reduces anti-HLA alloreactivity and shortens waiting time to cardiac transplantation in highly sensitized left ventricular assist device recipients. Circulation 1999: 100 II: 229-35.
13. Appel JZ, Hartwig MG, Davis RD, Reinsmoen NL. Utility of peritransplant and rescue intravenous immunoglobulin and extracorporeal immunoadsorption in lung transplant recipients sensitized to HLA antigens. Hum Immunol 2005: 66: 378-86.
14. Jordan SC, Quartel AW, Czer LS et al. Posttransplant therapy using high-dose human immunoglobulin (intravenous gammaglobulin) to control acute humoral rejection in renal and cardiac allograft recipients and potential mechanism of action. Transplantation 1998: 66: 800-5.
15. Casadei DH, Del C rial M, Opelz G et al. A randomized and prospective study comparing treatment with high-dose intravenous immunoglobulin with monoclonal antibodies for rescue of kidney grafts with steroid-resistant rejection. Transplantation 2001: 71: 53-8.
16. Moger V, RaviShankar MS, Sakjuja V et al. Intravenous immunoglobulin with monoclonal antibodies for rescue of kidney grafts with steroid-resistant rejection. Transplantation 2004: 77: 1455-6.
17. Yeh JH, Chen WH, Chiu HC, Bai CH. Clearance studies during subsequent sessions of double filtration plasmapheresis. Artif Organs 2006: 30: 111-4.
18. Okafor C, Ward DM, Mokrzycki MH, Weinstein R, Clark P, Balogun RA. Introduction and overview of therapeutic apheresis. J Clin Apher 2010: 25: 240-49.
19. Tanabe K. Double-filtration plasmapheresis. Transplantation 2007: 84: S30-2.
20. Braun N, Gutenberger S, Erley CM, Risler T. Immunoglobulin and circulating immune complex kinetics during immunoadsorption onto protein A sepharose. Transfus Sci 1998: 19 (Suppl): 25-31.
21. Zachary AA, Montgomery RA, Leffell MS. Desensitization protocols improving access and outcome in transplantation. Clin Appl Immunol Rev 2005: 5: 373-95.
22. Montgomery RA, Zachary AA. Transplanting patients with a positive donor-specific crossmatch: a single center's perspective. Pediatr Transplantation 2004: 8: 535-42.
23. Sonnenday CJ, Ratner LE, Zachary AA et al. Preemptive therapy with plasmapheresis/intravenous immunoglobulin allows successful live donor renal transplantation in patients with a positive cross-match. Transplant Proc 2002: 34: 1614-6.
24. Zachary AA, Montgomery RA, Ratner LE et al. Specific and durable elimination of antibody to donor HLA antigens in renal-transplant patients. Transplantation 2003: 76: 1519-25.
25. Montgomery RA, Zachary AA, Racusen LC et al. Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidney to be successfully transplanted into cross-match positive recipients. Transplantation 2000: 70: 887-95.
26. Warren DS, Montgomery RA. Incompatible kidney transplantation: lessons from a decade of desensitization and paired kidney exchange. Immunol Res 2010: 47: 257-64.
27. Schweitzer EJ, Wilson JS, Fernandez-Vina M. A high panel-reactive antibody rescue protocol for cross-match positive live donor kidney transplant. Transplantation 2000: 70: 1531-36.
28. Gloor JM, DeGoey SR, Pineda AA et al. Overcoming a positive crossmatch in living-donor kidney transplantation. Am J Transplant 2003: 34: 1017-23.
29. Thielke JJ, West-Thielke PM, Herren HL et al. Living donor kidney transplantation across positive crossmatch: the University of Illinois at Chicago experience. Transplantation 2009: 87: 268-73.
30. Flores-Gama F, Mondragón-Ramirez GA, Bochicchio- Riccardelli T. Desensitization and renal transplant: plasmapheresis/IVIG standard dose in patients with high immunologic risk. Cir Cir 2009: 77: 369-74.
31. Furth S, Neu AM, Hart J, Zachary A, Colomban P, Fivush BA. Plasmapheresis, intravenous cytomegalovirus-specific immunoglobulin and reversal of antibody-mediated rejection in a pediatric renal transplant recipient: a case report. Pediatr Transplant 1999: 3: 149-49.
32. Rocha PN, Butterly DW, Greenberg A et al. Beneficial effect of plasmapheresis and intravenous immunoglobulin on renal allograft survival of patients with acute humoral rejection. Transplantation 2003: 75: 1490-5.
33. White NB, Greenstein SM, Cantafio AW et al. Successful rescue therapy with plasmapoheresis and intravenous immunoglobulin for acute humoral renal transplant rejection. Transplantation 2004: 78: 772-74.
34. Lehrich RW, Rocha PN, Reinsmoen N et al. Intravenous immunoglobulin and plasmapheresis in acute humoral rejection: experience in renal allograft transplantation. Hum Immunol 2005: 66: 350-58.
35. Ibernon M, Gil-Vernet S, Carrera M et al. Therapy with plasmapheresis and intravenous immunoglobulin for acute humoral rejection in kidney transplantation. Transplant Proc 2005: 37: 3743-5.
36. Pisani BA, Mullen Gm, Malinowska K et al. Plasmapheresis with intravenous immunoglobulin G is effective in patients with elevated panel reactive antibody prior to cardiac transplantation. J Heart Lung Transplant 1999: 18: 701-6.
37. Leech SH, Lopez-Cepero M, LeFor WM et al. Management of the sensitized cardiac recipient: the use of plasmapheresis and intravenous immunoglobulin. Clin Transplant 2006: 20: 476-84.
38. Pollock-BarZiv SM, Den Hollander N, Ngan BY et al. Pediatric heart transplantation in human leukocyte antigen sensitized patients: evolving management and assessment of intermediate-term outcomes in a high-risk population. Circulation 2007: 116 (Suppl 1): 172-8.
39. Alexandre GP, Squifflet JP, DeBruyere M et al. Present experiences in a series of 26 ABO-incompatible living donor renal allografts. Transplant Proc 1987: 19: 4538-48.
40. Ishida H, Mayamoto N, Shirakawa H et al. Evaluation of immunosuppressive regimens in ABO-incompatible living kidney transplantation - single center analysis. Am J Transplant 2007: 7: 825-31.
41. Tanabe K, Ishida H, Shimizu T, Omoto K, Shirakawa H, Tokumoto T. Evaluation of two different preconditioning regimens for ABO-incompatible living kidney donor transplantation. A comparison of splenectomy vs. rituximab-treated non-splenectomy preconditioning regimens. Contrib Nephrol 2009: 162: 61-74.
42. Gloor JM, Stegall MD. ABO incompatible kidney transplantation. Curr Opin Nephrol Hypertens 2007: 16: 529-34.
43. Sonnenday CJ, Warren DS, Cooper M et al. Plasmapheresis, CMV hyperimmune globulin, and anti-CD20 allow ABO-incompatible renal transplantation without splenectomy. Am J Transplant 2004: 4: 1315-22.
44. Segev DL, Simpkins CE, Warren DS et al. ABO incompatible high titer renal transplantation without splenectomy or anti-CD20 treatment. Am J Transplant 2005: 5: 2570-5.
45. Montgomery RA, Locke JE, King KE et al. ABO incompatible renal transplantation: a paradigm ready for broad implementation. Transplantation 2009: 87: 1246-55.
46. Tobian AAR, Shirey RS, Montgomery RA et al. ABO antibody titer and risk of antibody-mediated rejection in ABO-incompatible renal transplantation. Am J Transplant 2010: 10: 1247-53.
47. Gloor MM, DeGoey S, Ploeger N et al. Persistence of low levels of alloantibody after desensitization in crossmatch-positive living-donor kidney transplantation. Transplantation 2004: 78: 221-7.
48. Zachary AA, Montgomery RA, Jordan SC, Reinsmoen NL, Claas FJH, Reed EF. 14th International HLA and immunogenetics workshop: report on understanding antibodies in transplantation. Tissue Antigens 2007: 69 (Suppl 1): 160-73.
49. Zachary AA, Leffell MS. Barriers to successful transplantation of the sensitized patient. Expert Rev Clinc Immunol 2010: 6: 449-60.
50. Jindra PR, Zhang X, Mulder A et al. Anti-HLA antibodies can induce endothelial cell survival or proliferation depending on their concentration. Transplantation 2006: 82: S33-5.
51. Narayanan K, Jaramillo A, Phelan DL, Mohanakumar T. Pre-exposure to sub-saturating concentrations of HLA class I antibodies confers resistance to endothelial cells against antibody complement-mediated lysis by regulating Bad through the phosphatidylinositol 3-kinase/Akt pathway. Eur J Immunol 2004: 34: 2303-12.
52. Zhang X, Reed EF. Effect of antibodies on endothelium. Am J Transplant 2009: 9: 2459-65.
53. Locke JE, Zachary AA, Warren DS. Proinflammatory events are associated with significant increases in breadth and strength of HLA-specific antibody. Am J Transplant 2009: 9: 2136-9.
54. Kopchaliiska D, Zachary AA, Montgomery RA, Leffell MS. Reconstitution of peripheral allospecific CD19+ B-cell subsets after B-lymphocyte depletion therapy in renal transplant patients. Transplantation 2009: 87: 1394-401.
55. Zachary AA, Montgomery RA, Leffell MS. Factors associated with and predictive of persistence of donor-specific antibody after treatment with plasmapheresis and intravenous immunoglobulin. Hum Immunol 2005: 66: 364-70.
56. Montgomery RA. Renal transplantation across HLA and ABO antibody barriers: integrating paired donation into desensitization protocols. Am J Transplant 2010: 10: 449-57.